BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29735754)

  • 1. An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.
    Kazmi F; Yerino P; McCoy C; Parkinson A; Buckley DB; Ogilvie BW
    Drug Metab Dispos; 2018 Aug; 46(8):1066-1074. PubMed ID: 29735754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters.
    Kim S; Kim DK; Shin Y; Jeon JH; Song IS; Lee HS
    Molecules; 2020 Oct; 25(19):. PubMed ID: 33050066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
    Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
    Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of Sutherlandia frutescens for herb-drug interaction.
    Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
    Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
    Ebner T; Ishiguro N; Taub ME
    J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
    Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
    Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions.
    Tong Z; Yerramilli U; Surapaneni S; Kumar G
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):869-74. PubMed ID: 24627218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Inhibitory Effects of APINACA on Human Major Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Drug Transporters.
    Kim S; Choi WG; Kwon M; Lee S; Cho YY; Lee JY; Kang HC; Song IS; Lee HS
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31430908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort.
    Ma J; Beers B; Manohar R; Roe S; Colacino JM; Kong R
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00748. PubMed ID: 33749127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of
    Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
    Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
    Yu RZ; Warren MS; Watanabe T; Nichols B; Jahic M; Huang J; Burkey J; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Apr; 26(2):111-7. PubMed ID: 26959999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions.
    Liu S; Wang Z; Chan E; Zhao Y; Kang J; Zhang X; Tian X
    Chem Biol Interact; 2022 Jan; 352():109775. PubMed ID: 34910929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
    Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
    Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the Drug Interaction Potential of Unconjugated and GalNAc
    Shemesh CS; Yu RZ; Warren MS; Liu M; Jahic M; Nichols B; Post N; Lin S; Norris DA; Hurh E; Huang J; Watanabe T; Henry SP; Wang Y
    Mol Ther Nucleic Acids; 2017 Dec; 9():34-47. PubMed ID: 29246313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
    Zhang H; Ou YC; Su D; Wang F; Wang L; Sahasranaman S; Tang Z
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00870. PubMed ID: 34664792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes.
    Chen N; Cui D; Wang Q; Wen Z; Finkelman RD; Welty D
    Xenobiotica; 2018 Jun; 48(6):637-646. PubMed ID: 28730856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
    Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
    Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.
    Zhang Q; Zhang Y; Boer J; Shi JG; Hu P; Diamond S; Yeleswaram S
    Drug Metab Dispos; 2017 Jun; 45(6):612-623. PubMed ID: 28283500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
    Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
    Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.